Cohen Omri, Lange Kfir, Budnik Ivan, Tamarin Ilia, Brutman-Barazani Tami, Barg Assaf Arie, Rosenberg Nurit, Lubetsky Aharon, Kenet Gili, Levy-Mendelovich Sarina
National Hemophilia Center, Institute of Thrombosis and Hemostasis, Sheba Medical Center, Tel HaShomer, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Pediatr Blood Cancer. 2022 Nov;69(11):e29929. doi: 10.1002/pbc.29929. Epub 2022 Aug 23.
Heparin-induced thrombocytopenia (HIT) is rare among pediatric patients. The diagnosis of HIT depends upon clinical decision tools to assess its pretest probability, supported by laboratory evidence of anti-platelet factor 4 (anti-PF4)/heparin antibodies.
To compare the use of the 4Ts score clinical decision tool, clinical characteristics, and laboratory findings between pediatric and adult patients with suspected HIT.
We compiled all pediatric patients in our center for whom HIT testing was performed during the years 2015-2021. These were compared with a cohort of consecutive adult patients. Laboratory diagnosis of HIT was performed with particle gel immunoassay (PaGIA) as screening test and confirmed by an automated latex-enhanced immunoturbidimetric assay (LIA) and/or by functional flow cytometry assay (FCA).
The cohort included 34 children (under 18 years) and 105 adults. Adults mostly received heparins for thromboembolism prophylaxis and treatment (72.4%, n = 76), and were more frequently treated with low-molecular-weight heparin (LMWH). Children were mostly exposed during cardiopulmonary bypass and extracorporeal membrane oxygenation (ECMO, 61.8%, n = 21), and were more frequently treated with unfractionated heparin (UFH). Compared with adults, children had significantly higher 4Ts scores. Nevertheless, adults had a slightly higher rate of a positive diagnosis of HIT. Six out of 16 adults with confirmed HIT presented with thrombosis (37.5%), whereas all three pediatric patients with HIT presented with thrombosis (p = .087).
4Ts scores are higher in children compared with adult patients for whom laboratory tests for HIT were obtained. A potentially higher incidence of thrombosis in children with HIT may be attributable to the severity of underlying illness.
肝素诱导的血小板减少症(HIT)在儿科患者中较为罕见。HIT的诊断依赖于临床决策工具来评估其检测前概率,并由抗血小板因子4(抗PF4)/肝素抗体的实验室证据支持。
比较疑似HIT的儿科和成年患者使用4Ts评分临床决策工具的情况、临床特征及实验室检查结果。
我们汇总了2015年至2021年期间在本中心进行HIT检测的所有儿科患者。将这些患者与一组连续的成年患者进行比较。采用颗粒凝胶免疫测定法(PaGIA)作为筛查试验进行HIT的实验室诊断,并通过自动乳胶增强免疫比浊法(LIA)和/或功能性流式细胞术检测法(FCA)进行确认。
该队列包括34名儿童(18岁以下)和105名成年人。成年人大多因血栓栓塞预防和治疗接受肝素治疗(72.4%,n = 76),且更频繁地接受低分子量肝素(LMWH)治疗。儿童大多在体外循环和体外膜肺氧合(ECMO)期间接触肝素(61.8%,n = 21),且更频繁地接受普通肝素(UFH)治疗。与成年人相比,儿童的4Ts评分显著更高。然而,成年人的HIT确诊率略高。16名确诊HIT的成年人中有6人出现血栓形成(37.5%),而3名患有HIT的儿科患者均出现血栓形成(p = 0.087)。
与接受HIT实验室检测的成年患者相比,儿童的4Ts评分更高。HIT患儿血栓形成发生率可能更高,这可能归因于基础疾病的严重程度。